Cyclooxygenase-2 and angiogenesis in prostate cancer

Cancer Biology and Therapy

Volumn 4, Issue 8, 2005, Pages 813-814

  Tkacz, Victoria L ^a   Tohnya, Tanyifor M ^b,c   Figg, William D ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; COX 2; Immunohistochemistry; Inflammation; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

ANGIOGENESIS; CHRONIC INFLAMMATION; DRUG MECHANISM; HUMAN; MICROVASCULARIZATION; MICROVASCULATURE; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY; ARTICLE; CHRONIC DISEASE; ENZYMOLOGY; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROSTATE TUMOR; PROSTATITIS; VASCULARIZATION;

CHRONIC DISEASE; CYCLOOXYGENASE 2; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROSTATITIS;

EID: 33745528143     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.8.2089     Document Type: Short Survey

References (17)

1. Jemal A, Thomas A, Murray T and Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD. Anti-angiogenesis therapeutic strategies in prostate cancer. Cancer Metastasis Rev 2002; 21:93-106.
3. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004; 215:1-20.
4. van Moorselaar RJ and Voest EE. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002; 197:239-50.
5. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26:1170-81.
6. Hughes C, Murphy A, Martin C, Sheils O and O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58:673-84.
7. Wang W, Bergh A and Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005; 11:3250-6.
8. Figg WD, Kruger EA, Price DK, Kim S and Dahut WD. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002; 20:183-94.
9. Chapple KS, Scott N, Guillou PJ, Coletta PL and Hull MA. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol 2002; 198:435-41.
10. Davies GL. Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 2003; 86:495-9.
11. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001; 7:1325-32.
12. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002; 33:213-9.
13. Williams CS, Tsujii M, Reese J, Dey SK and DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105:1589-94.
14. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2005; 53:232-40.
15. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun 2005; 332:800-7.
16. Mukherjee R, Edwards J, Underwood MA and Bartlett JM. The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer. BJU Int 2005; 96:62-6.
17. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351:1707-9.